The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Stock of the week: NVIDIA: The Best Company in the World?
Semiconductor stocks show a muted reaction to Nvidia’s report
Rheinmetall shares rise nearly 4% amid geopolitical tensions in Europe
Uber’s strategic purchase: Acquisition of Delivery Hero